- Home
- RGF vs SBFM Comparison
RGF vs SBFM Comparison
Compare RGF & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGF
- SBFM
- Stock Information
- Founded
- RGF 2016
- SBFM 2006
- Country
- RGF United States
- SBFM United States
- Employees
- RGF N/A
- SBFM N/A
- Industry
- RGF Packaged Foods
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- RGF Consumer Staples
- SBFM Health Care
- Exchange
- RGF Nasdaq
- SBFM Nasdaq
- Market Cap
- RGF 8.3M
- SBFM 3.7M
- IPO Year
- RGF 2021
- SBFM N/A
- Fundamental
- Price
- RGF $0.36
- SBFM $3.14
- Analyst Decision
- RGF Hold
- SBFM
- Analyst Count
- RGF 1
- SBFM 0
- Target Price
- RGF $0.50
- SBFM N/A
- AVG Volume (30 Days)
- RGF 1.2M
- SBFM 90.8K
- Earning Date
- RGF 11-08-2024
- SBFM 11-11-2024
- Dividend Yield
- RGF N/A
- SBFM N/A
- EPS Growth
- RGF N/A
- SBFM N/A
- EPS
- RGF N/A
- SBFM N/A
- Revenue
- RGF $156,379,000.00
- SBFM $30,481,982.00
- Revenue This Year
- RGF $23.67
- SBFM $86.70
- Revenue Next Year
- RGF N/A
- SBFM $126.76
- P/E Ratio
- RGF N/A
- SBFM N/A
- Revenue Growth
- RGF 18.88
- SBFM 109.82
- 52 Week Low
- RGF $0.21
- SBFM $2.42
- 52 Week High
- RGF $2.75
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- RGF 45.74
- SBFM 52.62
- Support Level
- RGF $0.33
- SBFM $2.85
- Resistance Level
- RGF $0.40
- SBFM $3.05
- Average True Range (ATR)
- RGF 0.04
- SBFM 0.14
- MACD
- RGF 0.00
- SBFM 0.03
- Stochastic Oscillator
- RGF 56.82
- SBFM 85.29
About RGF The Real Good Food Company Inc.
The Real Good Food Company Inc is an high-growth, branded, health- and wellness-focused frozen food company. It develops, markets, and manufactures delicious and convenient comfort foods designed to be high in protein, low in sugar, and made from gluten- and grain-free ingredients that are intended to be sold in the health and wellness segment of the frozen food category. All of its revenue is derived from the United States.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.